Harrow Inc
HROW34.930USD
+3.560+11.35%
Fechamento 07/11, 16:00（ET）Cotações atrasadas em 15 min
1.25BValor de mercado
PerdaP/L TTM
Mais detalhes de Harrow Inc Empresa
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Informações da empresa
Código da empresaHROW
Nome da EmpresaHarrow Inc
Data de listagemFeb 08, 2013
Fundado em2006
CEOMr. John P. Saharek
Número de funcionários382
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 08
Endereço1A Burton Hills Blvd
CidadeNASHVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal37215
Telefone16157334731
Sitehttps://www.harrow.com/
Código da empresaHROW
Data de listagemFeb 08, 2013
Fundado em2006
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Investidores
Investidores
Proporção
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
23.15%
Hedge Fund
18.11%
Individual Investor
15.07%
Investment Advisor
12.93%
Research Firm
2.04%
Pension Fund
0.45%
Bank and Trust
0.33%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Other
27.83%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
340
26.58M
72.44%
-3.00M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.48%
First Trust Small Cap Growth AlphaDEX Fund
0.4%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Small-Mid Multifactor ETF
0.09%
First Trust Multicap Growth Alphadex Fund
0.07%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção0.76%
iShares U.S. Pharmaceuticals ETF
Proporção0.48%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.4%
iShares Micro-Cap ETF
Proporção0.19%
ProShares Ultra Nasdaq Biotechnology
Proporção0.13%
Invesco Nasdaq Biotechnology ETF
Proporção0.11%
Vanguard US Momentum Factor ETF
Proporção0.1%
Fidelity Small-Mid Multifactor ETF
Proporção0.09%
First Trust Multicap Growth Alphadex Fund
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
